Overview

VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment

Status:
Completed
Trial end date:
2018-11-21
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, PK and safety study of VNRX-5133 and VNRX-5022 when co-administered in male and female subjects with varying levels of renal impairment and healthy normal controls.
Phase:
Phase 1
Details
Lead Sponsor:
Venatorx Pharmaceuticals, Inc.
Collaborator:
National Institutes of Health (NIH)